glp-1 overview Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development PDB-101: Molecule of the Month:

Stress management helps prevent emotional eating, which can ruin your weight loss plans

These medications mimic the actions of the endogenous incretin hormone GLP-1 by enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety.[1] Incretin hormones also exert effects across multiple organ systems, including cardiovascular, renal, and skeletal systems.[1] Owing to these pleiotropic mechanisms, the clinical use of GLP-1RAs has expanded exponentially, both for diabetes and for a broadening spectrum of diseases and conditions.[2] Obesity plays a central role in the pathogenesis and progression of T2DM, yet many traditional glucose-lowering therapies are associated with weight gain.[3] The observation that GLP-1RAs not only improve glycemic control but also result in significant weight loss marked a paradigm shift in diabetes pharmacotherapy, prompting investigation into their therapeutic potential in individuals without diabetes to treat obesity and related comorbidities.[4] Subsequently, large-scale cardiovascular and kidney outcome trials have demonstrated additional benefits of GLP-1RAs, further supporting their use in high-risk populations independent of diabetes status.[4] These trials resulted in a rapid evolution of the clinical landscape for GLP-1RAs in the last decade, with growing evidence supporting their role in treating obesity, cardiovascular disease, chronic kidney disease (CKD), and other metabolic-related disorders.[520] This expansion reflects both their favorable efficacy profile and their broader physiological effects

There are also warnings about thyroid Ccell tumors in animal studies for some drugs, and clinician screening is important

To this end, tirzepatide robustly stimulated glucagon secretion in isolated human islets, further emphasizing a meaningful contribution of tirzepatide activity at the GIPR (Figure 2) 45

To ensure regulatory compliance, partner with suppliers who have demonstrated experience and approvals in your target markets (e.g., FDA for the US, EMA for Europe, NMPA for China)